Associated Papers
Genomics-Driven Precision Medicine in Pediatric Solid Tumors.
Suthapot P et al.
Cancers, 2023
Molecular and Functional Heterogeneity of Primary Pancreatic Neuroendocrine Tumors and Metastases.
Guo Y et al.
Neuroendocrinology, 2023
37232011 (PubMed )
Supplement: Supplementary_material-Suppl.7-s7.xls › Table_S6
Role and significance of c-KIT receptor tyrosine kinase in cancer: A review.
Sheikh E et al.
Bosnian Journal of Basic Medical Sciences, 2022
Computational analysis reveals histotype-dependent molecular profile and actionable mutation effects across cancers.
Heim D et al.
Genome Medicine, 2018
30442178 (PubMed )
Supplement: 13073_2018_591_MOESM4_ESM.xlsx › Table_S2
The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacological Research, 2018
The strength and cooperativity of KIT ectodomain contacts determine normal ligand-dependent stimulation or oncogenic activation in cancer.
Reshetnyak AV et al.
Molecular Cell, 2015
A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
Allegra M et al.
The Journal of Investigative Dermatology, 2014
Prevalence of c-KIT mutations in gonadoblastoma and dysgerminomas of patients with disorders of sex development (DSD) and ovarian dysgerminomas.
Hersmus R et al.
Plos One, 2012
Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I.
Orlova KV et al.
Case Reports in Oncology, 0
31043947 (PubMed )
Supplement: cro-0012-0109-s01.pdf
Select a paper to view details